HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Yoshiki Sawa Hikaru Matsuda Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ahmet, I. Articles by Matsuda, H. Search for Related Content PubMed PubMed Citation Articles by Ahmet, I. Articles by Matsuda, H. Related Collections Molecular biology

J Thorac Cardiovasc Surg 2002;124:957-963
© 2002 The American Association for Thoracic Surgery

Cardiopulmonary Support and Physiology (CSP)

Gene transfection of hepatocyte growth factor attenuates cardiac remodeling in the canine heart: A novel gene therapy for cardiomyopathy

From the First Department of Surgery, Osaka University Medical School, Osaka, Japan.

Received for publication Feb 18, 2002. Revisions requested April 30, 2002; revisions received May 6, 2002. Accepted for publication May 22, 2002. Address for reprints: Yoshiki Sawa, MD, First Department of Surgery, Osaka University Medical School, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan (E-mail: sawa{at}surg1.med.osaka-u.ac.jp).

Objective: Hepatocyte growth factor, a potent angiogenic agent, is unique in having the effects of antiapoptosis and antifibrosis. In the present study we used the rapid pacing-induced heart failure canine model to investigate the effect of gene transfection of hepatocyte growth factor on the failing heart.
Methods: Four weeks after onset of rapid pacing, either the human hepatocyte growth factor gene (160 µg; hepatocyte growth factor group, n = 7) or empty vector (control group, n = 7) was directly injected into the left ventricular myocardium by means of the hemagglutinating virus of Japan liposome method.
Results: At 4 weeks after gene transfection, the left ventricular global function, assessed by means of pressure-volume loop analysis, was improved in the hepatocyte growth factor group as preload-recruitable stroke work (percentage of baseline: 80% ± 20% from 38% ± 15% before gene transfection, P = .005), whereas it was not changed in the control group (50% ± 18% from 50% ± 18%). Weekly echocardiography showed that this improvement began in the week after gene transfer. The hearts in the hepatocyte growth factor group had a large wall thickness, large myocyte diameter, high capillary density, low fibrotic area fraction, and low density of apoptotic nuclei revealed by means of histologic analysis compared with that in the control group. Myocardial perfusion flow, assessed with color microspheres, was increased in the hepatocyte growth factor group (percentage of baseline: 79% ± 16% from 48% ± 14%, P = .010), whereas it was reduced in the control group (30% ± 12% from 45% ± 17%).
Conclusions: Gene transfection of hepatocyte growth factor promoted angiogenesis, improved perfusion, decreased fibrosis and apoptosis, promoted recovery from myocyte atrophy, and thereby attenuated cardiac remodeling and improved myocardial function in the failing heart. It is a novel gene therapy for human heart failure.

This article has been cited by other articles:

				R. R. Edelman Can MR Imaging Be Used to Determine the Efficacy of Gene Therapy in the Heart? Radiology, October 1, 2008; 249(1): 1 - 2. [Full Text] [PDF]

				H. Hata, G. Matsumiya, S. Miyagawa, H. Kondoh, N. Kawaguchi, N. Matsuura, T. Shimizu, T. Okano, H. Matsuda, and Y. Sawa Grafted skeletal myoblast sheets attenuate myocardial remodeling in pacing-induced canine heart failure model J. Thorac. Cardiovasc. Surg., October 1, 2006; 132(4): 918 - 924. [Abstract] [Full Text] [PDF]